Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (618)	8/4/2007 1:18:04 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 668

Hedgehog--Genentech has a 50-patient phase I systemically administered Hedgehog antagonist in 'locally advanced or metastatic solid tumors that have relapsed after first and second line therapy or for whom no clinically beneficial therapy exists' Wyeth is funding five Curis researchers for hedgehog for neurologic disorders. Wnt signaling pathway, discovery phase, is with Genentech and no research funding for Curis. In house, CUDC-101 is designed to inhibit EGFR, Her2, and "Target A" which should be revealed in the fall. "formal toxicology testing will be initiated early in the fourth quarter of 2007" June 30, 2007 cash, cash equivalents, marketable securities and investments totaled $30,228,000 and there were 49,533,950 shares of common stock outstanding.